Global Biopsy Devices Market Size

85
business

Summary

According to BlueWeave Consulting, Global Biopsy Devices Market is estimated to be USD 3.8 billion by 2026 from USD 2.53 billion in 2019, at a CAGR of 6% from 2020 to 2026.

Press Release

The biopsy is a process to execute surgical removal of tissue from an organ to conclude the presence or extent of disease, generally cancerous and inflammatory conditions. It is usually performed by surgeons, radiologists, and interventional cardiologists. Biopsies can be executed on any organ using precise biopsy devices as a confirmatory test for cancer and celiac diseases. The use of each biopsy device varies according to the type of organ under consideration. Conventional biopsy devices can complement progressive imaging technologies, such as MRI-guided biopsy, stereotactic-guided biopsy, ultrasound-guided biopsy, CT scan, and others, to execute biopsy with correctness and minimal invasiveness. These integrated procedures are used to do biopsies on body organs such as the lungs, liver, and kidneys.

Global Biopsy Devices MarketĀ 

Growth Drivers

Rising cases of cancerĀ 

The growing occurrence of cancer universal and the occurrence of untapped opportunities in developing economies, especially of Asia Pacific, along with refining healthcare infrastructure in these regions, are amid the key trends stoking market growth. Surging demand for effective diagnostic procedures for cancer is also predictable to work in favor of the market.

Restraint

Financial constraintĀ 

Growing cancer-related expenditure is triggering the need for actual diagnostic procedures. Government and healthcare regulatory bodies worldwide are engaged continuously in curbing high costs related to the treatment of cancer. Primary and secondary healthcare centers in emerging nations are boosting patients to experience regular diagnostic examinations. Biopsy devices involve a comparatively lesser number of hospital stays and, therefore, is economically viable.

Impact of COVID-19 in industry

During the COVID-19 epidemic, screenings have fallen sharply. Cervical cancer repeats were down 68 percent in the US across the first 15 weeks of 2020, while breast cancer checking downfall by 17 percent, with more significant declines in areas where the outbreak was sturdiest.

About Us

BlueWeave Consulting is a one-stop solution for market intelligence regarding various products and services online & offline. We offer comprehensive market research reports by analyzing both qualitative and quantitative data to boost up the performance of your business solution. BWC has built its reputation from the scratches by delivering quality performance and nourishing long-lasting relationships with its clients. We are one of the promising digital market intelligence generation company providing unique solutions for blooming your business and making the morning, more rising & shining.